TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Excessive corneal staining area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pancreas survival
Endpoint domain: Mortality/survival
Primary endpoint: Moderate or severe rejection episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Pancreas thrombosis
Endpoint domain: Adverse events/effects
Primary endpoint: overall median survival time
Endpoint domain: Mortality/survival
Primary endpoint: Immune response measured by ELISA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroresponse rate against mumps measured by PRNT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 25-hydroxyvitamin D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CTx-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PINP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: C(max) of dinaciclib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC([I]) of dinaciclib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACL QOL score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 50% or greater reduction in depressive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-point decrease in PHQ-9 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life improvement (social/family, emotional, functional, physical)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: CNS functioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Panic locus of control orientation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Excellent outcomes at 3 months
Endpoint domain: Mortality/survival
Primary endpoint: peptic ulcer cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: MLS score changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: edema score changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: LCSS pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: global QOL today score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: mean morning plasma cortisol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: 24-hour urinary cortisol excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Correction rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spontaneous labour rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration between initial correction and birth process
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trail Making Test‐B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rey Complex Figure Test Delay Recall
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: P3b latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Levels of α‐synuclein oligomers in CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oligomers/total‐α‐synuclein ratio in CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: smoking reward
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reinforcement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC) of unbound paclitaxel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unbound and total paclitaxel clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebrovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in LF values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fatty acid composition in liver tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: n-6/n-3 PUFA ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of cardiovascular morbidity and mortality
Endpoint domain: Mortality/survival
Primary endpoint: Reduction of fatal and non-fatal cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of stroke morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bone metastasis occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Total number of new AKs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean time of development of new AKs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Local adverse events intensity
Endpoint domain: Adverse events/effects
Primary endpoint: Prediagnostic mammographic density (MD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Gastrointestinal tolerance profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Functional residual capacity (FRC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Splenic arterial heterogeneity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Hounsfield units in areas of splenic enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive CST
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite measurement of 'failure'
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: depressive symptom remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improved well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total-cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: SMI time index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Critical heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: glucose variability indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency of AAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Goal attainment scaling scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain experienced during SPT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: initial rebleed rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inpatient stay duration
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: cost within 6 months
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Hospitalizations per resident
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: 30sCST
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: normalized knee extensor muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: normalized knee flexor muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Sodium concentration of transplanted kidneys
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Sodium gradient of transplanted kidneys
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Pharmacokinetic parameters (t(½), AUC(0-∞), C(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical treatment time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention of a straight MCP joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of PIP contracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in HbA1c levels from baseline to week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in serum fasting glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 5-year FFR
Endpoint domain: Mortality/survival
Primary endpoint: Deaths because of disease progression
Endpoint domain: Mortality/survival
Primary endpoint: vision-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Increase in posterior corneal elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in global severity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of sexual thoughts
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Satisfaction with mental and physical aspects of sexuality
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Use of rescue salbutamol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalence of high-grade oesophageal lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Post-day 1 neonatal mortality
Endpoint domain: Mortality/survival
Primary endpoint: HINT thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left Ventricular (LV) volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: bladder preservation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrence free rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Digit failure
Endpoint domain: Mortality/survival
Primary endpoint: Child behavior problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of ineffective parenting strategies
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Confidence in dealing with behavior concerns
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in pancreatic β‐cell function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cost per kilogram of weight loss
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean Life Expectancy (LE)
Endpoint domain: Mortality/survival
Primary endpoint: Incremental Cost-Effectiveness Ratios (ICERs)
Endpoint domain: Resource use
Primary endpoint: Improvement in energy
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Compression depth accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication Adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Positive attitudes to antipsychotic medication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: post-procedural pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No signs of disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fewer occasions of coitus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fewer coital partners
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: greater use of condoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance of fundamental nursing skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical remission at week 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perforation repair rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average airway bone gap improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for multiple-drug therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to 1 mm ST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Exercise time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cardiac ischemic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: target‐induced astigmatism vectors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: surgically induced astigmatism vectors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: indices of success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreased lung function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: N-terminal-prohormone of brain natriuretic peptide (NT-proBNP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fixator gestation period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vgamma9Vdelta2 T-cell expansion and maturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HIV-specific CD8 T-cell responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in sleep difficulties
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Mean utility value
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Nighttime sleep disorder score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Device replacement frequency
Endpoint domain: Adverse events/effects
Primary endpoint: Grade 3/4 neutropenia rates
Endpoint domain: Adverse events/effects
Primary endpoint: Spontaneous Passage Rate (SPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time for passage of stones
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analgesia consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 24 h systolic and diastolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Score reduction of TCM Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score reduction of Kubota's Water Drinking Test Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean systemic exposure (AUC0-24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of peripheral blood pre‐switch IgD+CD27+ memory B cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean difference in fiber intake (FFQ - 4DFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mental rotation reaction time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WOMAC Pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucagon response during OGTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: need for antihypertensive therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent change in UAER
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean percentage of unbound 14C-tamsulosin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measures of DH (Dentin Hypersensitivity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EQ‐5D utility score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Duke Activity Status Index score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of in‐hospital visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Urge to defecate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Defecation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: impairments of psychomotor performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relative beta‐1 activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjective assessments
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: relative alpha activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of ocular itching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of conjunctival redness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 16.1-km road TT completion time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perceived impact on clinical care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cure rate of hydroceles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days absent from work
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Improvement in recurrent depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Moderate-strenuous physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emotional quality of life
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: pelvic pressure ulcer healing rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Locoregional tumour control at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Free plasma TRP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loudness change rates of N1/P2 tangential dipole activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of closed pockets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean reduction in PPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficiency of initial treatment phase
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: memory function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: cognitive performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Reduction of behavioral symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in Theory of Mind skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Reduction in the size of BICRs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: change in systolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Beta-thromboglobulin (B-TG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Platelet Count (PLT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to attain TOF ratio of 0.9
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: New VTE (Venous Thromboembolism)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: reduced heart rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: better everyday anxiety regulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Measured peak plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: myoclonus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Control of nocturnal hypoventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Diagnosis or exclusion of previous proximal-vein thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: wet weight sputum cleared
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dyspnoea during daily life
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum running speed (Vmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum blood lactate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Anastomotic strictures
Endpoint domain: Adverse events/effects